Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05756764 · ClinicalTrials.gov registry record
Anti-obesity Pharmacotherapy and Inflammation
A clinical trial of Obesity, sponsored by Louisiana State University Health Sciences Center in New Orleans.
- Active
- Registry status
- 30
- Enrollment target
- 2
- Study locations
NCT05756764: Active study of Obesity, sponsored by Louisiana State University Health Sciences Center in New Orleans.
NCT05756764 is a study of Obesity that is active but no longer recruiting, run by Louisiana State University Health Sciences Center in New Orleans. The registered enrollment target is 30 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05756764, a study of Obesity, is active but no longer recruiting, sponsored by Louisiana State University Health Sciences Center in New Orleans.
- ACTIVE NOT RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study evaluates the relationship between weight loss, circulating inflammatory markers and lipids from 24 patients before and after 6 months of pharmacotherapy as a standard of care for anti-obesity treatment
Primary Outcome
Weight Loss Percentage (Pounds lost divided by starting weight (in pounds) multiplied by 100)
Conditions Studied
Interventions
- DRUG Tirzepatide
- DRUG Semaglutide
- DRUG Topiramate
- DRUG Phentermine
- DRUG Phentermine-Topiramate combination
Study Locations (2)
Louisiana
- LSU Clinical & Translational Research Center (CTRC - - LSUHSC-NO - New Orleans
- Ochsner Health System - Biospecimen - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-06-01 |
| Est. Completion | 2026-02-20 |
What the registry record for NCT05756764 still lists
NCT05756764 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 5 interventions - of which Tirzepatide is the first listed.
NCT05756764 reports a single indexed study location in Louisiana.
Frequently Asked Questions
What is clinical trial NCT05756764 about?
NCT05756764 is a clinical study titled "Anti-obesity Pharmacotherapy and Inflammation". This study evaluates the relationship between weight loss, circulating inflammatory markers and lipids from 24 patients before and after 6 months of pharmacotherapy as a standard of care for anti-obesity treatment
What is the current status of trial NCT05756764?
This trial is currently active not recruiting. The enrollment target is 30 participants. The study started on 2023-06-01. Estimated completion is 2026-02-20.
What conditions does trial NCT05756764 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT05756764?
The interventions under investigation include: Tirzepatide (DRUG), Semaglutide (DRUG), Topiramate (DRUG), Phentermine (DRUG), Phentermine-Topiramate combination (DRUG).
Who is sponsoring clinical trial NCT05756764?
This trial is sponsored by Louisiana State University Health Sciences Center in New Orleans, which has 45 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05756764 being conducted?
This trial has 2 study locations across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05756764's enrollment target sits among peer trials
30 851st of 1053 higher than 173 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Hip Flexion Feedback System for Exercise Monitoring in Individuals With Osteoarthritis and Obesity
RECRUITING · Phase 1
-
Metabolic Adaptations to Weight Loss With and Without Exercise
RECRUITING · NA
-
Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial
RECRUITING · NA
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Tai Chi as a Novel Strategy to Increase Physical Activity Among Adults Pursuing Metabolic and Bariatric Surgery
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI